SCHEMBL24192106

SCHEMBL24192106

CCOC(=O)c1cc(C)[nH]c1/C=C1\C(=O)Nc2ccc(O)cc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 5/20 0.67
KDR P35968 3/20 0.67
RET P07949 8/20 0.52
TLK2 Q86UE8 1/20 0.52
PDGFRB P09619 3/20 0.51
ALK Q9UM73 4/20 0.51
FLT3 P36888 3/20 0.51
ABL1 P00519 2/20 0.51
FGFR1 P11362 2/20 0.51
MAPT P10636 2/20 0.47
APP P05067 1/20 0.47
SNCA P37840 1/20 0.47
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
GMNN O75496 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
CSF1R P07333 1/20 0.46
KIT P10721 1/20 0.46
SRC P12931 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2114264 0.91 RET (0.65) PDPK1KDRRETTLK2PDGFRB
SCHEMBL30454169 0.91 RET (0.65) PDPK1KDRRETTLK2PDGFRB
SCHEMBL2114263 0.91 RET (0.65) PDPK1KDRRETTLK2PDGFRB
SCHEMBL24192389 0.88 KDR (0.53) PDPK1KDRRETTLK2PDGFRB
SCHEMBL2113963 0.87 KDR (0.70) PDPK1KDRRETPDGFRBALK
SCHEMBL30452948 0.87 KDR (0.70) PDPK1KDRRETPDGFRBALK
SCHEMBL2113961 0.87 KDR (0.70) PDPK1KDRRETPDGFRBALK
SCHEMBL24192207 0.85 PDPK1 (0.67) PDPK1KDRRETPDGFRBALK
SCHEMBL24191807 0.83 KDR (0.47) PDPK1KDRRETTLK2PDGFRB
SCHEMBL24192453 0.81 KDR (0.45) PDPK1KDRRETTLK2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257396-A1 MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2023-08-17 US disclosed
US-20230257396-A1 MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2023-08-17 US disclosed
WO-2022011123-A1 MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2022-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257396-A1 MACROCYCLES AND THEIR USE VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD PDPK1 784/4885KDR 1921/4885RET 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.